Serum-starved U87 glioblastoma cells were treated with increasing concentrations of TGF-β in the presence or absence of either 30 μM EGCG or 10 μM galunisertib, a selective TGF-β receptor type I (TGF-βRI) kinase inhibitor [37]. Here, TGFB1 is linked to glioblastoma.